Objective-TRPM7 (transient receptor potential cation channel, subfamily M, member 7) is a ubiquitously expressed bifunctional protein comprising a transient receptor potential channel segment linked to a cytosolic α-type serine/threonine protein kinase domain. TRPM7 forms a constitutively active Mg 2+ and Ca 2+ permeable channel, which regulates diverse cellular processes in both healthy and diseased conditions, but the physiological role of TRPM7 kinase remains largely unknown. Approach and Results-Here we show that point mutation in TRPM7 kinase domain deleting the kinase activity in mice (Trpm7
T RPM7 (transient receptor potential cation channel, subfamily M, member 7) belongs to the melastatin-related transient receptor potential subfamily of transient receptor potential channels 1, 2 and forms a constitutively active divalent cation-selective channel that regulates many cellular processes, including cell cycle, apoptosis, and cell death. 1, [3] [4] [5] Global ablation of TRPM7 or deletion of its kinase domain results in early embryonic lethality in mice. 5, 6 In vitro, TRPM7 deficiency in DT40 cells and also other cell types results in the depletion of [Mg 2+ ] i and growth arrest in the presence of normal extracellular [Mg 2+ ]. 1, 4 TRPM7-mediated cation influx has been detected in megakaryocytes, 7 and dysfunction of TRPM7 channel, but not its kinase activity, causes macrothrombocytopenia in humans and mice because of an imbalanced Mg 2+ homeostasis in megakaryocytes and platelets. 8 
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TRPM7 contains a cytosolic α-kinase domain with an Mg 2+ /ATP-binding site, which is critical for the catalytic activity, and its mutation on lysine 1646 abolishes the kinase activity. 4, 9 Autophosphorylation of the TRPM7 kinase domain on serine 1511/1567 enhances kinase-substrate interactions leading to their serine/threonine phosphorylation. [10] [11] [12] [13] Although it has been demonstrated that the kinase domain of TRPM7 directly binds PLC (phospholipase C) isoforms, 14 contradictory findings exist on the functional consequence of this interaction. Depending on the used heterologous expression system in vitro, GPCR (G-protein-coupled receptor)-mediated PLCβ activation can either positively or negatively modulate TRPM7 channel activity. [14] [15] [16] Recently, it has been shown that PLCγ2-an important regulator of immunoreceptor tyrosine-based activation motif (ITAM) receptor-mediated Ca 2+ signaling-is phosphorylated by TRPM7 kinase 17 ; however, the physiological significance of this modification is not fully understood. PLC-mediated PIP2 (phosphatidylinositol 4,5-bisphosphate) hydrolysis induces Ca 2+ store depletion thereby enhancing store-operated Ca 2+ entry (SOCE), which is regulated by functional coupling of the Ca 2+ sensor STIM1 (stromal interaction molecule 1) and the Ca 2+ channel Orai1 in mammalian nucleated cells and platelets. 18 Recent reports provided in vitro evidence that TRPM7 kinase regulates Ca 2+ store content, STIM1 function, and SOCE in chicken B cells. 19 It has been reported that mice subjected to the transient middle cerebral artery occlusion (tMCAO) model of ischemic stroke display an upregulation of TRPM7 protein expression in neurons. In contrast, downregulation of TRPM7 in the ischemic brain prevented neuronal necrosis. 20, 21 Consequently, it was speculated that the increased TRPM7 channel activity may enhance Ca 2+ influx and induce neuronal cell death in the ischemic brain. 22 However, the role of TRPM7 kinase domain in the process of thromboinflammation and stroke and the associated signaling pathways remain elusive.
Here we show that deletion of the TRPM7 kinase activity in mice (Trpm7 R/R ) inhibits (hem)ITAM-PLCγ2 and PAR (protease-activated receptor)-PLCβ3-mediated intracellular Ca 2+ mobilization, and partially blocks SOCE in platelets, resulting in protection of mice from arterial thrombosis and thromboinflammatory brain infarction in a model of ischemic stroke.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Mg
2+ Homeostasis and TRPM7 Channel Activity in Kinase-Dead TRPM7 Knock-In Mice
Recently, we identified TRPM7 as a key regulator of Mg 2+ homeostasis in megakaryocytes, which is critical for platelet biogenesis in the bone marrow (BM). 8 To dissect the role of TRPM7 kinase and channel function in vivo, a kinase-dead knock-in mouse strain was generated (Trpm7 Figure ID in the online-only Data Supplement), and there was no evidence for a role of TRPM7 kinase in platelet biogenesis because platelet size, number, and morphology, 8 as well as the expression of major platelet glycoprotein receptors, including GPVI (glycoprotein VI) and CLEC-2 (C-type lectin-like receptor), and platelet life span, were indistinguishable from controls ( Figure IIA and IIB in the online-only Data Supplement). Figure 1A ). However, Trpm7 R/R platelets were able to spread on fibrinogen with similar kinetics as WT control platelets, indicating that TRPM7 kinase did not affect integrin outsidein signaling ( Figure IIC in thrombin) or arachidonic acid were normal. However, at threshold concentration of CRP, collagen, and thrombin, the aggregation response was impaired in Trpm7 R/R platelets ( Figure 1B) . Amplification of GPVI signaling requires activation of the linker for activation of T cells (LAT) complex through spleen tyrosine kinase (Syk), as well as thromboxane A2 and ATP/serotonin release. We found that pretreatment with the Syk inhibitor BI1002494 could mimic the aggregation defects of Trpm7 R/R platelets in response to GPVI agonists, whereas the TP (thromboxane receptor) blocker SQ29548 had no effect. In contrast, thrombin-dependent aggregation was normalized in the presence of SQ29548 ( Figure 1B and 1C) . Moreover, thrombin or CRP-mediated serotonin and ATP release from δ-granules was significantly reduced in Trpm7 R/R platelets at threshold agonist concentrations, whereas thromboxane A2 release was not affected ( ] i ) through the release of Ca 2+ from intracellular stores and subsequent SOCE and receptor-operated Ca 2+ entry are prerequisites for platelet integrin αIIbβ3 activation, as well as degranulation. 18, 23 To investigate whether altered Ca 2+ responses accounted for the impaired α-and δ-granule secretion in Trpm7 R/R platelets, GPVI-ITAM and GPCR signaling were analyzed by fluorimetric determination of agonist-induced changes in [Ca 2+ ] i . In line with the reduced integrin activation and degranulation, Ca 2+ -store release was significantly reduced in Trpm7 R/R platelets in response to CRP or thrombin ( Figure 2B ), indicating a combined GPVI and PAR receptor signaling defect on platelet activation. As a consequence of the abnormal Ca 2+ store release, the GPVI-PLCγ2-and thrombin-PLCβ-induced Ca 2+ influx was also reduced in Trpm7 R/R platelets and could be normalized by treatment with BI1002494 ( Figure 2C ). To study whether TRPM7 kinase could directly contribute to the regulation of SOCE, the sarco/endoplasmic reticulum Ca 2+ ATPase inhibitor thapsigargin was used to bypass the GPVI-and PAR receptor-induced Ca 2+ mobilization defect and directly modulate SOCE. Despite the normal basal cytoplasmic Ca 2+ level and thapsigargin-induced Ca 2+ store release, SOCE was strongly reduced in Trpm7 R/R platelets, suggesting a specific role of TRPM7 kinase in the regulation of STIM1-mediated SOCE in platelets (Figure 2Di ).
TRPM7
GPVI and PAR receptor signaling involves a series of phosphorylation events that finally enhance PLCγ2 and PLCβ activity, respectively, which mediates the hydrolysis of PIP 2 into inositol triphosphate (IP 3 ) and diacylglycerol. 23 (Figure 2Dii) .
The GPVI signalosome is regulated by Src family kinase Lyn and the tyrosine kinase Syk, which modulates the enzymatic activity of PLCγ2 and other signaling molecules. 25 In agreement with our previous results ( Figures 1B, 2B , and 2C), we found delayed tyrosine phosphorylation of Syk , and PLCγ2 Y759 in Trpm7 R/R platelets upon low-dose CRP stimulation, whereas the phosphorylation was normal at high-dose CRP stimulation ( Figure 3A ; Figure IIIB in the online-only Data Supplement). Furthermore, phosphorylation of serine residue 729 on PKCϵ (PKC [protein kinase C] epsilon type)-a downstream effector of PLCγ2-was also diminished. In sharp contrast, phosphorylation of Lyn Y507 at the inhibitory loop of the enzyme was unaltered ( Figure 3A) . Based on these findings, we hypothesized that a proximal regulator, such as Syk, could be affected in Trpm7R/R platelets. In addition, PLCβ3 phosphorylation was also reduced upon stimulation with different concentrations of thrombin ( Figure 3B ; Figure , and PLCγ2 Y759 in Trpm7 R/R platelets upon rohdocytin stimulation ( Figure 4C ).
TRPM7 Kinase Is Essential for Occlusive Arterial Thrombus Formation
To study whether TRPM7-mediated modulation of PLCγ2 activity plays a significant regulatory role in thrombosis and hemostasis, we next analyzed the ability of Trpm7 R/R platelets to form thrombi on fibrous collagen in a heparinized whole blood perfusion system to prevent thrombin generation. Here, WT platelets adhered to the collagen fibers and formed 3-dimensional aggregates within 2 to 4 minutes, which consistently grew resulting in large thrombi at the end of the perfusion period, whereas Trpm7 R/R platelets exhibited reduced adhesion and impaired formation of 3-dimensional thrombi ( Figure 5A ). To test whether these defects also translated into impaired arterial thrombosis in vivo, we induced a mechanical injury on the abdominal aorta and then monitored blood flow with an ultrasonic flow probe. Although in WT mice, 19 of 21 (90%) arteries occluded during the observation period, only 11 of 19 (58%) Trpm7 R/R arteries formed occlusive thrombi, and these showed significantly prolonged occlusion times compared with WT control (WT, 297±89 versus Trpm7 R/R , 454±189 s; Figure 5B ). Next, thrombus formation was induced by injuring mesenteric arterioles with FeCl 3 and thrombus formation was monitored by intravital fluorescence microscopy. The time to first appearance of thrombi <10 µm was similar in the mesenteric arterioles of WT and Trpm7 R/R mice (WT, 506±95 versus Trpm7 R/R , 528±117 s; Figure IV in Figure 5D ), demonstrating an important role of TRPM7 kinase in primary hemostasis. These findings revealed that TRPM7 kinase-dependent modulation of GPVI signaling is a critical determinant for thrombus growth and stability in vivo.
TRPM7 Kinase Plays an Important Role in Ischemic Stroke
To assess a possible functional role of TRPM7 kinase in the pathogenesis of acute ischemic brain infarction, we next analyzed neuronal damage in WT and Trpm7 R/R mice subjected to tMCAO. In this model of ischemic stroke, a filament is advanced to the middle cerebral artery to occlude the vessel for 1 hour followed by reperfusion after removal of the filament, which typically results in further infarct growth during the next 24 hours (reperfusion injury). 26 Strikingly, infarct volumes in Trpm7 R/R brains after 24 hours were dramatically reduced to <40% of those seen in WT controls ( Figure 6A ). To determine whether this protective effect was because of an increased resistance of Trpm7 R/R neurons to ischemia or to altered blood cell function, BM chimeras were generated by injecting WT BM cells into lethally irradiated Figure 6B , left). Importantly, in serial magnetic resonance imaging on day 7 after tMCAO, we did not observe delayed infarct progression or intracranial hemorrhage ( Figure 6B, right) . The reduction in infarct size was functionally relevant because global neurological (Bederson score) and motor (Grip test) functions ( Figure 6C ) were improved in Trpm7 R/R
/BM
WT and WT/BM Trpm7R/R mice, when compared with WT mice 1 day after tMCAO. Infarct growth in the acutely ischemic brain involves closely intertwined inflammatory and thrombotic pathomechanisms, referred to as thromboinflammation, in which platelets are key mediators. 27 To further clarify the extent to which altered platelet function contributed to the protection of WT/BM Trpm7R/R mice from tMCAO-induced neuronal damage, WT mice rendered thrombocytopenic by anti-GPIbα (glycoprotein Ib alpha) antibody injection were transfused with WT or Trpm7 R/R platelets and subsequently subjected to tMCAO. 28, 29 Remarkably, WT mice that had received Trpm7 R/R platelets developed significantly smaller brain infarcts compared with controls, and also global neurological and motor function were significantly improved ( Figure 6D ), clearly demonstrating that TRPM7 kinase activity in platelets contributes to the development of ischemic brain infarction.
Discussion
The α-kinase protein family comprises various members including TRPM6, 30 TRPM7, 31 and eEF2 serine/threonine kinases. 32 To date, only few substrates of TRPM7 kinase have been identified in vitro, namely myosin IIa, 33 PLCγ2, 17 and annexin-1. 12 Although tyrosine kinase-dependent platelet signaling has been extensively studied, the physiological importance of serine/threonine phosphorylation in ITAM receptor signaling triggered by TPRM7 kinase or other α-kinases is entirely unknown. The GPVI signalosome is regulated by Src family kinases, which bind the cytoplasmic tail of GPVI, and are critical for initial activation of the GPVI signalosome. However, they can also inhibit platelet activation through phosphorylation of immunoreceptor tyrosine-based inhibition motifs on PECAM (platelet-endothelial cell adhesion molecule)-1 and modulation of PKC activity. 35, 36 The tyrosine kinase Syk transduces the signal from the GPVI/FcRγ (Fc receptor gamma)-chain to LAT, which in turn induces the recruitment of different adaptors and PLCγ2 from the cytosol. It has been shown that several PLC isoforms can directly bind the kinase domain of TRPM7, and that PLCγ2 is phosphorylated by TRPM7 kinase, but the physiological in vivo relevance of these interactions remained elusive. 2, 14, 17 Our study now demonstrates that ablation of TRPM7 kinase activity strongly inhibited the tyrosine phosphorylation cascade downstream of GPVI and CLEC-2 involving the Syk-LAT-PLCγ2 signaling axis. Because pretreatment of Trpm7 R/R platelets with Syk inhibitor BI1002494 normalized aggregation responses, we speculate that TPRM7 kinase indeed regulates Syk or upstream effectors in the (hem) ITAM signaling complex. In addition, PLCβ3 activity is regulated by TRPM7 kinase, which suggests an essential role for PLC-mediated Ca 2+ store depletion during platelet activation. It has been shown that several phosphorylation events on serine residues of STIM1 are involved in the modulation of SOCE 37 ; however, this mechanism and the regulatory kinases have not been investigated in platelets. Recently, using heterologous expression in DT40 cells, it has been shown that TRPM7 regulates SOCE. Furthermore, Ca 2+ store content and the refilling process of the Ca 2+ store are also regulated by TRPM7, indicating a functional link between TRPM7 and STIM1. In line with this, we show in vivo that TRPM7 kinase activity indeed regulates SOCE in platelets. However, further investigation is required to establish the exact molecular mechanisms by which the channel and kinase domain of TRPM7 regulate STIM1-mediated SOCE.
TRPM7 has been shown to be expressed in the human vascular system and to modulate Mg 2+ homeostasis, cell growth, and proliferation in vascular smooth muscle and endothelial cells 38 and abnormal expression of the channel has been linked to the development of cardiovascular diseases. 39 In the present study, we demonstrate that the kinase activity of TRPM7 regulates platelet activation in primary hemostasis and arterial thrombosis, establishing the TRPM7 kinase as a potential target to modulate platelet activity in thromboinflammatory disease settings. Our results suggest that the combined GPVI signaling defects and reduced SOCE account for the thrombus instability and antithrombotic protection of Trpm7 R/R mice. Moreover, a balanced Ca 2+ and Mg 2+ homeostasis plays a pivotal role in neuronal survival under ischemic conditions. Indeed, Mg 2+ was found to be a potent Ca 2+ antagonist thereby protecting ischemic neurons from Ca 2+ overload. 40 In support of this, a reduced intracellular Mg 2+ concentration was detected in the infarcted rat and human brain, and conversely experimental hypomagnesaemia resulted in increased infarct volumes after photothrombosis. [41] [42] [43] Using BM chimeras and adoptive platelet transfer, we could decipher the contribution of TRPM7 kinase function in platelets from its function in endothelial cells and neurons. The improved motor function and reduced infarct volumes in Trpm7 R/R /BM WT mice clearly showed that besides platelets, TRPM7 kinase activity in brain tissue, most likely in neurons and glia cells, may also be a critical factor for the progression of ischemic brain infarction. 20 Interestingly, in WT mice subjected to tMCAO, a 2-to-3-fold increase in TRPM7 expression has been observed in the cortex after reperfusion, 44, 45 which likely resulted in a Ca 2+ overload and contributed to neuronal death, as well as infarct progression. 46 In support of this, knockdown of TRPM7 prevented neuronal cell death under ischemic conditions in vivo. 21 Based on these tMCAO studies, inhibition of TRPM7 channel activity was proposed as a promising potential therapeutic target. 47 Surprisingly, our results showed that disruption of TRPM7 kinase activity either in platelets or in neurons is sufficient to protect the brain from the thromboinflammatory cerebral I/R injury. These results suggest that under pathological conditions, increased TRPM7 channel activity cannot overcome the protective effect of abolished TRPM7 kinase function in Trpm7 R/R mice. Consequently, we conclude that TRPM7 kinase activity, which further accelerates PLC-mediated Ca 2+ mobilization and SOCE, rather than enhanced TRPM7 channel activity, plays a dominant role in the development of stroke. The finding that selective disruption of TRPM7 kinase function does not cause intracranial bleeding in the ischemic brain and only moderately influences hemostasis in mice highlights TRPM7 kinase as a potential therapeutic target to develop safe antithrombotic or anti-thromboinflammatory agents.
